4/11/2011, 5:59 pm
COMRADES! I want to alert you to this gross misuse of the word "progress"-
AAN: Laquinimod Cuts Relapses, Progression in MS
By John Gever, Senior Editor, MedPage Today
Published: April 11, 2011
HONOLULU -- The investigational drug laquinimod, in development for relapsing-remitting multiple sclerosis (MS), reduced the relapse rate as well as disease progression in a placebo-controlled phase III trial, according to data released here.
Relapses were 23% less common with the drug relative to placebo, and progression of disability was cut 36%, according to a late-breaking abstract slated for presentation on Friday at the American Academy of Neurology (AAN) meeting, by Giancarlo Comi, MD, of the University Vita-Salute San Raffaele in Milan, Italy.
A securities firm broke the embargo on the abstract, AAN staff said, forcing them to allow other media to report the data.
Besides slowing progression and relapses, laquinimod treatment in the two-year, 1,106-patient ALLEGRO study reduced the number of new T2 and cumulative gadolinium-enhancing lesions on MRI scans, Comi and colleagues indicated.
In addition, progression of brain atrophy was reduced 32.8%. FULL STORY
This use of the word "progress" MUST STOP NOW! It sounds like a deadly disease, not the Glorious Coming World of Next Tuesday™
AAN: Laquinimod Cuts Relapses, Progression in MS
By John Gever, Senior Editor, MedPage Today
Published: April 11, 2011
HONOLULU -- The investigational drug laquinimod, in development for relapsing-remitting multiple sclerosis (MS), reduced the relapse rate as well as disease progression in a placebo-controlled phase III trial, according to data released here.
Relapses were 23% less common with the drug relative to placebo, and progression of disability was cut 36%, according to a late-breaking abstract slated for presentation on Friday at the American Academy of Neurology (AAN) meeting, by Giancarlo Comi, MD, of the University Vita-Salute San Raffaele in Milan, Italy.
A securities firm broke the embargo on the abstract, AAN staff said, forcing them to allow other media to report the data.
Besides slowing progression and relapses, laquinimod treatment in the two-year, 1,106-patient ALLEGRO study reduced the number of new T2 and cumulative gadolinium-enhancing lesions on MRI scans, Comi and colleagues indicated.
In addition, progression of brain atrophy was reduced 32.8%. FULL STORY
This use of the word "progress" MUST STOP NOW! It sounds like a deadly disease, not the Glorious Coming World of Next Tuesday™